2nd Cardiac Safety Conference

Posted:
20
November 2007

2nd Cardiac Safety ConferenceBrief Description: ICH E14 QT Guidance were finalised (step 4) in May 2005. However, implementation of the new guidance (step 5) seems to have taken a different pace in different ICH regions, with US FDA leading the trend and Japan PMDA still developing their own version. The controversy regarding the predictive value of different non-clinical and clinical QT assays (including the TQT study itself) continue to underline the regional regulatory variations. As global experience is building up, Thorough QT (TQT) study designs are improving, sample size dropping and the use of positive control(s) becoming more sophisticated. The potential benefits of capturing and viewing multidimensional aspects of continuous QT and morphology data are gathering momentum with innovative technologies and methodologies coming up. Analysing and reporting QT data is also evolving while various TQT outcome scenarios are emerging. Concentration-effect modelling, promoted by US FDA, is increasingly taking a central role in the analysis and reporting of QT data. At the same time certain therapeutic classes, such as oncology and biological products, are still cast with uncertainty and face inconsistent regulatory requirements in the various regions.At the other end of the drug development spectrum, ongoing issues involving post marketing pharmacovigilance continue to make headlines. Cardiac Adverse Reactions, whether repolarisation-based, thrombosis-related or other are reported increasingly, involving a variety of drug classes. While legal and financial liabilities are still strong driving forces for cardiac safety pharmacovigilance, new public and regulatory initiatives are endorsing more proactive risk management and risk minimisation plans. These topics and others will be interactively discussed during the conference.Date: December 3 - 4, 2007Location: Dorint Praha Don Giovanni Hotel, Prague, Czech RepublicStand Number: 4

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more